Zepp Health Introduces Zepp OS 4: Redefining Wearable Intelligence by Integrating OpenAI’s GPT-4o into its Amazfit Smartwatches
Amazfit Active becomes the world's first smartwatch under €200 to fully-integrate AI. MILPITAS, Calif., July 2, 2024 /PRNewswire/ -- Zepp Health Corporation ("Zepp Health") (NYSE: ZEPP), a global leader in smart wearables and health technology, unveils Zepp OS 4, a groundbreaking advancement in wearable technology. This latest iteration integrates OpenAI's GPT-4o most advanced system, producing safer and more useful...
Saudi Arabia to host the first-ever International Conjoined Twins Conference on 24-25 November 2024: KSrelief
RIYADH, Saudi Arabia, July 2, 2024 /PRNewswire/ -- The United Nations has announced that 24 November 2024 will be 'World Conjoined Twins Day' and will be observed each year, to emphasize the need to address the condition of conjoined twins, advocate for their treatment and care, and promote their well-being and social...
Clarivate Identifies Six Breakthrough MedTech Trends in 2024 Set to Unlock New Industry Opportunities
New report highlights challenges and opportunities in resilient MedTech industry LONDON, July 2, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today announced the release of the MedTech Trends to Watch 2024 report, the second installment in a two-part series offering a predictive analysis of emerging...
Menarini’s cell based non-invasive prenatal technology demonstrates high resolution detection of fetal genomic abnormalities from a simple maternal blood draw
Data presented at the 2024 FMF (Fetal Medicine Foundation) World Congress in Lisbon, Portugal shows the potential for an automated system to deliver genomic profiles of fetal cells that is highly concordant with the genomic analysis obtained from invasive procedures. Results of a large clinical validation study show that Menarini Silicon Biosystems' fetal cell based noninvasive...
PharmAbcine’s Phase 1 Clinical Trial of PMC-403 for Neovascular Age-related Macular Degeneration Advances to Both Single-dose of 4mg and Multiple-dose of 3mg
Safety Review Committee (SRC) approves single 3mg dose for the third cohort in Phase 1 trial of PMC-403 DAEJEON, South Korea, July 2, 2024 /PRNewswire/ -- PharmAbcine, Inc. ("PharmAbcine" or the "Company") (KOSDAQ: 208340), a clinical-stage public company developing next generation therapeutics to treat medical unmet needs, announced today the...
HiRO acquires CRO DeltaMed Solutions, continues to expand cross-border operations in the US
WILMINGTON, Del., July 2, 2024 /PRNewswire/ -- Harvest Integrated Research Organization (HiRO), a full-service, boutique global CRO, is excited to announce its latest strategic move with the successful acquisition of DeltaMed Solutions, an emerging CRO with a robust foothold in the US. The acquisition, advised by Evercore as financial advisor, marks HiRO's third CRO acquisition since its establishment in 2020. Following...
Altos Biologics Files Approval of Aflibercept Biosimilar
DAEJEON, South Korea, July 2, 2024 /PRNewswire/ -- Alteogen Inc. (KOSDAQ: 196170) announced on July 1st that its subsidiary, Altos Biologics Inc. has submitted Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for an aflibercept biosimilar ALT-L9, developed by Alteogen. The Phase 3 clinical trial for ALT-L9 commenced with initial clinical trial approval in 2022, involving...
Innovent Announces Oral Presentation at the ESMO Gastrointestinal Cancers Congress 2024 on Latest Clinical Data of Anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
SAN FRANCISCO and SUZHOU, China, July 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced oral presentation of the latest Phase 1 clinical data of an innovative anti-CLDN18.2 ADC (IBI343) for the...
Lions Celebrate a Successful Year of Service at the 106th Lions International Convention
OAK BROOK, Ill., July 2, 2024 /PRNewswire/ -- Lions International celebrated several milestones during the 106th Lions International Convention in Melbourne, Australia. Nearly 10,000 Lions attended this pinnacle event to reconnect with Lions from around the world, discover innovative ways to grow and support clubs and commemorate another year of serving communities...
Bridgewest Perth Pharma gains strategic edge with noted Australian Executive John Van Der Wielen on Board
PERTH, Australia, July 2, 2024 /PRNewswire/ -- Bridgewest Perth Pharma, global pharmaceutical holding company with NovaCina CDMO division and LumaCina pharmaceutical supply division, announces the addition of renown Australian executive John Van Der Wielen to Board of Directors. Van Der Wielen will focus on Australian expansion programs for all three entities. Renown Australian...
